<DOC>
	<DOCNO>NCT00436865</DOCNO>
	<brief_summary>The polycystic ovary syndrome lead cause female infertility United States . The disorder affect approximately 6-10 % woman reproductive age . It widely accept `` insulin resistance '' may responsible infertility syndrome . Women insulin resistant body respond insulin 's action handle sugar normally . Because insulin resistance , woman polycystic ovary syndrome also high risk develop type 2 diabetes . We previously show D-chiro-inositol ( DCI ) , substance naturally find body help insulin 's action , lack woman polycystic ovary syndrome . Not enough DCI may lead insulin resistance . The purpose study determine weight loss help replenish body DCI help promote insulin 's action .</brief_summary>
	<brief_title>Insulin Polycystic Ovary Syndrome -- Weight Reduction Study</brief_title>
	<detailed_description>Insulin resistance present woman PCOS . Women PCOS high risk develop type 2 diabetes , presumably due insulin resistance accompany syndrome . Some action insulin may effect putative inositolphosphoglycan ( IPG ) mediator insulin action , evidence suggests deficiency specific D-chiro-inositol ( DCI ) -containing IPG may contribute insulin resistance individual impair glucose tolerance type 2 diabetes mellitus . A deficiency DCI may also contribute insulin resistance woman PCOS . In PCOS , three separate study show administration DCI , precursor DCI-IPG , woman PCOS improve glucose intolerance reduce circulate insulin , improved ovulatory function , decrease serum androgen . Serum triglyceride , HDL cholesterol blood pressure improve study well . Collectively , finding strongly suggest administration DCI improve insulin sensitivity woman PCOS , deficiency DCI may contribute insulin resistance disorder . Previous study group demonstrate woman PCOS , compare normal woman , ( ) great 5-fold increase renal clearance DCI , ( ii ) 50 % reduction circulate concentration DCI , ( iii ) decrease insulin-stimulated release DCI-IPG oral glucose tolerance test ( OGTT ) . Moreover , insulin sensitivity ( determine frequently sample intravenous glucose tolerance test [ FSIVGTT ] ) correlate inversely renal clearance DCI . In addition , appear obesity need present abnormality renal clearance DCI present PCOS , obesity seem effect DCI renal clearance normal woman . Our hypothesis obesity modulate renal clearance DCI woman PCOS , normal woman . A corollary hypothesis increase urinary DCI clearance lead reduction circulate DCI insulin-stimulated DCI-IPG release , aggravate insulin resistance woman PCOS . To test hypothesis , propose study follow specific aim : Specific Aims : Specific Aim 1 : Determine DCI renal clearance obese woman PCOS increase compare age- weight-matched , obese normal woman . In aim , determine obese woman PCOS ( ) increase renal clearance DCI , ( ii ) decrease circulating level DCI , ( iii ) decrease DCI-IPG release blood OGTT , compare age- BMI-matched , obese normal woman . Specific Aim 2 : Determine weight loss reduces DCI renal clearance obese woman PCOS , age- weight-matched obese normal woman . This aim determine weight loss reverse abnormality DCI handle PCOS . The effect weight loss ( ) renal clearance DCI , ( ii ) circulating level DCI , ( iii ) DCI-IPG release blood OGTT , compare obese woman PCOS age- BMI-matched obese normal woman . Specific Aim 3 : Determine change ( reduction ) DCI renal clearance result weight loss correlate change ( improvement ) insulin sensitivity obese woman PCOS independent weight loss . In Preliminary Studies , determine insulin sensitivity significant inverse relationship urinary DCI clearance . In aim , determine decrease DCI renal clearance weight loss obese woman PCOS improve insulin sensitivity independent degree weight loss ( via statistical adjustment degree weight loss covariate ) . Specific Aim 4 : Determine equivalent degree weight loss obese woman without PCOS associate ( ) great reduction DCI renal clearance , ( ii ) great improvement insulin sensitivity PCOS woman compare normal woman . To demonstrate whether improvement insulin sensitivity result improvement DCI handle independent weight loss , woman stratify degree weight loss . For degree weight loss , determine obese woman PCOS ( ) great reduction renal clearance DCI ( ii ) great improvement insulin sensitivity result weight reduction , compare weight-matched obese normal woman . If propose study confirm role obesity modulate DCI handle PCOS , substantially enhance understanding pathogenesis PCOS likely provide insight novel treatment strategy direct specifically IPG system normalization function .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Polycystic Ovary Syndrome</mesh_term>
	<criteria>Obese ( â‰¥ 30 kg/m2 ) premenopausal woman PCOS normal woman 1840 year age . PCOS woman : oligomenorrhea ( &lt; = 8 menstrual period annually ) , biochemical hyperandrogenemia ( elevated total free testosterone ) , normal thyroid function test serum prolactin , exclusion 21alphahydroxylase deficiency fast 17alphahydroxyprogesterone &lt; 200 ng/dl . Normal woman : regular monthly menses , normal serum total free testosterone . All woman : acceptable health basis interview , medical history , physical examination , laboratory test ( CBC , SMA20 , urinalysis ) , diet 3 month prior study enrollment , sign , witness informed consent , ability comply study requirement . Diabetes mellitus fast glucose OGTT , clinically significant pulmonary , cardiac , renal , hepatic , neurologic , psychiatric , infectious , neoplastic malignant disease ( nonmelanoma skin cancer ) . Documented suspected recent ( within one year ) history drug abuse alcoholism . Ingestion investigational drug within 3 month prior study onset . Pregnancy document urine hCG . PCOS woman : Change PCOS medication regimen ( oral contraceptive , spironolactone , insulin sensitizer ) within 3 month prior start study . Normal woman : history gestational diabetes , positive family history firstdegree relative diabetes , disorder link insulin resistance ( hypertension dyslipidemia ) , Use oral systemic contraceptive , spironolactone within 3 month prior start study , Use medication ( include OTC drug ) know affect insulin sensitivity metformin , rosiglitazone , pioglitazone , niacin , corticosteroid , beta blocker , calcium channel blocker thiazide diuretic within 3 month prior start study .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>